UNLABELLED: Myocardial hypoxia is an attractive target for diagnostic and prognostic imaging, but current approaches are insufficiently sensitive for clinical use. The PET tracer copper(II)-diacetyl-bis(N4-methylthiosemicarbazone) ((64)Cu-ATSM) has promise, but its selectivity and sensitivity could be improved by structural modification. We have therefore evaluated a range of (64)Cu-ATSM analogs for imaging hypoxic myocardium. METHODS: Isolated rat hearts (n = 5/group) were perfused with normoxic buffer for 30 min and then hypoxic buffer for 45 min within a custom-built triple-γ-detector system to quantify radiotracer infusion, hypoxia-dependent cardiac uptake, and washout. A 1-MBq bolus of each candidate tracer (and (18)F-fluoromisonidazole for comparative purposes) was injected into the arterial line during normoxia, and during early and late hypoxia, and their hypoxia selectivity and pharmacokinetics were evaluated. The in vivo pharmacokinetics of promising candidates in healthy rats were then assessed by PET imaging and biodistribution. RESULTS: All tested analogs exhibited hypoxia sensitivity within 5 min. Complexes less lipophilic than (64)Cu-ATSM provided significant gains in hypoxic-to-normoxic contrast (14:1 for (64)Cu-2,3-butanedione bis(thiosemicarbazone) (ATS), 17:1 for (64)Cu-2,3-pentanedione bis(thiosemicarbazone) (CTS), 8:1 for (64)Cu-ATSM, P < 0.05). Hypoxic first-pass uptake was 78.2% ± 7.2% for (64)Cu-ATS and 70.7% ± 14.5% for (64)Cu-CTS, compared with 63.9% ± 11.7% for (64)Cu-ATSM. Cardiac retention of (18)F-fluoromisonidazole increased from 0.44% ± 0.17% during normoxia to 2.24% ± 0.08% during hypoxia. In vivo, normoxic cardiac retention of (64)Cu-CTS was significantly lower than that of (64)Cu-ATSM and (64)Cu-ATS (0.13% ± 0.02% vs. 0.25% ± 0.04% and 0.24% ± 0.03% injected dose, P < 0.05), with retention of all 3 tracers falling to less than 0.7% injected dose within 6 min. (64)Cu-CTS also exhibited lower uptake in liver and lung. CONCLUSION: (64)Cu-ATS and (64)Cu-CTS exhibit better cardiac hypoxia selectivity and imaging characteristics than the current lead hypoxia tracers, (64)Cu-ATSM and (18)F-fluoromisonidazole.
UNLABELLED: Myocardial hypoxia is an attractive target for diagnostic and prognostic imaging, but current approaches are insufficiently sensitive for clinical use. The PET tracer copper(II)-diacetyl-bis(N4-methylthiosemicarbazone) ((64)Cu-ATSM) has promise, but its selectivity and sensitivity could be improved by structural modification. We have therefore evaluated a range of (64)Cu-ATSM analogs for imaging hypoxic myocardium. METHODS: Isolated rat hearts (n = 5/group) were perfused with normoxic buffer for 30 min and then hypoxic buffer for 45 min within a custom-built triple-γ-detector system to quantify radiotracer infusion, hypoxia-dependent cardiac uptake, and washout. A 1-MBq bolus of each candidate tracer (and (18)F-fluoromisonidazole for comparative purposes) was injected into the arterial line during normoxia, and during early and late hypoxia, and their hypoxia selectivity and pharmacokinetics were evaluated. The in vivo pharmacokinetics of promising candidates in healthy rats were then assessed by PET imaging and biodistribution. RESULTS: All tested analogs exhibited hypoxia sensitivity within 5 min. Complexes less lipophilic than (64)Cu-ATSM provided significant gains in hypoxic-to-normoxic contrast (14:1 for (64)Cu-2,3-butanedione bis(thiosemicarbazone) (ATS), 17:1 for (64)Cu-2,3-pentanedione bis(thiosemicarbazone) (CTS), 8:1 for (64)Cu-ATSM, P < 0.05). Hypoxic first-pass uptake was 78.2% ± 7.2% for (64)Cu-ATS and 70.7% ± 14.5% for (64)Cu-CTS, compared with 63.9% ± 11.7% for (64)Cu-ATSM. Cardiac retention of (18)F-fluoromisonidazole increased from 0.44% ± 0.17% during normoxia to 2.24% ± 0.08% during hypoxia. In vivo, normoxic cardiac retention of (64)Cu-CTS was significantly lower than that of (64)Cu-ATSM and (64)Cu-ATS (0.13% ± 0.02% vs. 0.25% ± 0.04% and 0.24% ± 0.03% injected dose, P < 0.05), with retention of all 3 tracers falling to less than 0.7% injected dose within 6 min. (64)Cu-CTS also exhibited lower uptake in liver and lung. CONCLUSION: (64)Cu-ATS and (64)Cu-CTS exhibit better cardiac hypoxia selectivity and imaging characteristics than the current lead hypoxia tracers, (64)Cu-ATSM and (18)F-fluoromisonidazole.
Authors: Paul McQuade; Katherine E Martin; Thomas C Castle; Michael J Went; Philip J Blower; Michael J Welch; Jason S Lewis Journal: Nucl Med Biol Date: 2005-02 Impact factor: 2.408
Authors: N Takahashi; Y Fujibayashi; Y Yonekura; M J Welch; A Waki; T Tsuchida; N Sadato; K Sugimoto; A Nakano; J D Lee; H Itoh Journal: Ann Nucl Med Date: 2001-06 Impact factor: 2.668
Authors: Jason L J Dearling; Jason S Lewis; Gregory E D Mullen; Michael J Welch; Philip J Blower Journal: J Biol Inorg Chem Date: 2001-09-08 Impact factor: 3.358
Authors: Jason S Lewis; Richard Laforest; Farrokh Dehdashti; Perry W Grigsby; Michael J Welch; Barry A Siegel Journal: J Nucl Med Date: 2008-06-13 Impact factor: 10.057
Authors: Maxwell G Handley; Rodolfo A Medina; Rowena L Paul; Philip J Blower; Richard Southworth Journal: Nucl Med Commun Date: 2013-10 Impact factor: 1.690
Authors: Stuart P McCluskey; Anna Haslop; Christopher Coello; Roger N Gunn; Edward W Tate; Richard Southworth; Christophe Plisson; Nicholas J Long; Lisa A Wells Journal: J Nucl Med Date: 2019-05-30 Impact factor: 10.057
Authors: Connie Yip; Philip J Blower; Vicky Goh; David B Landau; Gary J R Cook Journal: Eur J Nucl Med Mol Imaging Date: 2015-02-21 Impact factor: 9.236
Authors: I N Fleming; R Manavaki; P J Blower; C West; K J Williams; A L Harris; J Domarkas; S Lord; C Baldry; F J Gilbert Journal: Br J Cancer Date: 2014-12-16 Impact factor: 7.640
Authors: Salil Srivastava; Philip J Blower; Aisah A Aubdool; Robert C Hider; Giovanni E Mann; Richard C Siow Journal: Sci Rep Date: 2016-12-21 Impact factor: 4.379
Authors: Richard Southworth; Rafael Torres Martin de Rosales; Levente K Meszaros; Michelle T Ma; Gregory E D Mullen; Gilbert Fruhwirth; Jennifer D Young; Cinzia Imberti; Julia Bagunya-Torres; Erica Andreozzi; Philip J Blower Journal: Adv Inorg Chem Date: 2015-11-16 Impact factor: 3.282
Authors: Fiona Shaughnessy; Erika Mariotti; Karen P Shaw; Thomas R Eykyn; Philip J Blower; Richard Siow; Richard Southworth Journal: EJNMMI Res Date: 2014-08-01 Impact factor: 3.138